Olaparib is a potent inhibitor of both PARP-1 and PARP-2, with IC50 = 5 nM and 1 nM, respectively. Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways.
See how others have used Olaparib. Click on the entry to view the PubMed entry .
PMID: # 30784586 Munnur, D.|Somers, J.|Skalka, G.|Weston, R.|Jukes-Jones, R.|Bhogadia, M.|Dominguez, C.|Cain, K.|Ahel, I.|Malewicz, M.| et al. 2019. Cell Rep. 26: 2028-2036.e6.
PMID: # 30054449 2018. J. Cell Biol. 217: 3382-3397.
PMID: # 29784019 2018. J. Exp. Clin. Cancer Res. 37: 107.
PMID: # 28069876 Li, J. et al. 2017. Mol. Cancer Ther.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.